Fact CheckerSign in

NCT06742099Not yet recruitingEarly phase 1

The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion

Outcome of Intercostal Tube Insertion and Pleurodesis for Malignant Pleural Effusion

Source: ClinicalTrials.gov · Last updated 19 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Approximately half of all patients with metastatic cancer develop a malignant pleural effusion which is likely to lead to a significant reduction in quality of life secondary to symptoms such as dyspnoea and cough. The aim of pleurodesis in these patients is to prevent re-accumulation of the effusion and thereby of symptoms,and avoid the need for repeated hospitalization for thoracocentesis. Numerous clinical studies have been performed to try to determine the optimal pleurodesis strategy, and synthesis of the available evidence should facilitate this. The treatment of MPE is aimed at palliating symptoms since no intervention has been shown to improve survival in this population and since survival is generally limited in cancers that have spread to the pleural space. In this palliative setting, only patients symptomatic from their MPE should be submitted to further intervention. As well, further interventions in symptomatic patients should be limited to those patients who have experienced symptomatic improvement following initial therapeutic thoracentesis. The two main treatment approaches to MPE are to obliterate the pleural space via a pleurodesis procedure or to chronically drain the pleural cavity with Intercostal tube. The aims of this review were to ascertain the optimal procedure in cases of malignant pleural effusion in terms of patients' quality of life post procedure, recurrence of effusion.

Status (registry)
Not yet recruiting
Phase (registry)
Early phase 1
Study type
Interventional
Enrollment
20 (estimated)
First submitted
5 Dec 2024
Start date
30 Dec 2024
Primary completion date
15 Jun 2025
Lead sponsor
Assiut University
NCT number
NCT06742099

What you commit to

  • Study type: Interventional · Early phase 1
  • Planned participants: 20
  • From 30 Dec 2024 to the primary completion date, 15 Jun 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • All patients presented with pleural effusion other than malignant pleural effusion, including patients with debilitating diseases and terminal patients.

Who the study is looking for

  • All patients presented with malignant pleural effusion to Assiut University Hospital regardless of sex and age

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Assiut University hospital
Coordinator of this site? Confirm its status
AsyutEgyptUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.